{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:51:39Z","timestamp":1786729899911,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41582-020-00410-7","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:04:34Z","timestamp":1601039074000},"page":"593-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Spinal muscular atrophy \u2014 the dawning of a new era"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-0902","authenticated-orcid":false,"given":"Michelle A.","family":"Farrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-026X","authenticated-orcid":false,"given":"Matthew C.","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"410_CR1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert, D. D. et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205\u20131214 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"410_CR2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"410_CR3","unstructured":"Canadian Agency for Drugs and Technologies in Health. Nusinersen. CADTH, https:\/\/www.cadth.ca\/nusinersen (2017)."},{"key":"410_CR4","unstructured":"World Health Organization. Improving the transparency of markets for medicines, vaccines, and other health products. WHO, https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA72\/A72_ACONF2Rev1-en.pdf (2019)."},{"key":"410_CR5","unstructured":"Powell, T. & O\u2019Donnell, M. NICE appraisals of rare disease. House of Commons Library, https:\/\/researchbriefings.files.parliament.uk\/documents\/CDP-2019-0022\/CDP-2019-0022.pdf (2019)."},{"key":"410_CR6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo, D. C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul. Disord. 29, 842\u2013856 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"410_CR7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"DST Kariyawasam","year":"2020","unstructured":"Kariyawasam, D. S. T., Russell, J. S., Wiley, V., Alexander, I. E. & Farrar, M. A. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet. Med. 22, 557\u2013565 (2020).","journal-title":"Genet. Med."},{"key":"410_CR8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock, J. et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul. Dis. 7, 97\u2013100 (2020).","journal-title":"J Neuromuscul. Dis."},{"key":"410_CR9","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41436-019-0455-8","volume":"21","author":"KA Beauchamp","year":"2019","unstructured":"Beauchamp, K. A., Johansen Taber, K. A. & Muzzey, D. Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. Genet. Med. 21, 1948\u20131957 (2019).","journal-title":"Genet. Med."},{"key":"410_CR10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/jnnp-2019-322327","volume":"91","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam, D., Alexander, I. E., Kurian, M. & Farrar, M. A. Great expectations: virus-mediated gene therapy in neurological disorders. J. Neurol. Neurosurg. Psychiatry 91, 849\u2013860 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00410-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00410-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00410-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:42:21Z","timestamp":1632526941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00410-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1038\/s41582-020-00410-7","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"25 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.F. has received compensation as a member of the scientific advisory boards for Biogen, Roche and AveXis. These bodies had no role in the design or preparation of the article or decision to publish. M.C.K. is Editor-in-Chief of the <i>Journal of Neurology, Neurosurgery & Psychiatry<\/i> (BMJ Publishers, UK).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}